SCHEMBL1748591

SCHEMBL1748591

CCOC(=O)Cc1c(Cl)nc(Cl)nc1NC1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS2 P35228 2/20 0.44
NOS1 P29475 1/20 0.44
ALDH1A1 P00352 3/20 0.44
MAPT P10636 2/20 0.44
HTT P42858 2/20 0.44
NPC1 O15118 1/20 0.44
MAPK1 P28482 1/20 0.44
RAB9A P51151 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
CNR1 P21554 2/20 0.42
CNR2 P34972 1/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
NSD2 O96028 1/20 0.41
KDM4E B2RXH2 1/20 0.41
GPR119 Q8TDV5 1/20 0.40
LMNA P02545 2/20 0.40
THRB P10828 1/20 0.40
KDM1A O60341 1/20 0.40
EHMT2 Q96KQ7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1748337 0.81 ALDH1A1 (0.52) ALDH1A1MAPTHTTNPC1MAPK1
SCHEMBL4226011 0.79 NOS2 (0.46) NOS2NOS1ALDH1A1MAPTHTT
SCHEMBL29501996 0.77 ALDH1A1 (0.51) NOS2NOS1ALDH1A1MAPTHTT
SCHEMBL21591871 0.77 ALDH1A1 (0.51) NOS2NOS1ALDH1A1MAPTHTT
SCHEMBL30841705 0.77 ALDH1A1 (0.49) ALDH1A1MAPTHTTNPC1MAPK1
SCHEMBL12596581 0.77 GPR119 (0.52) ALDH1A1MAPTHTTNPC1MAPK1
SCHEMBL4024871 0.76 ALDH1A1 (0.47) ALDH1A1MAPTHTTNPC1MAPK1
SCHEMBL1748295 0.75 SSTR5 (0.52)
SCHEMBL1748313 0.73 SSTR5 (0.49)
SCHEMBL14682141 0.73 ALDH1A1 (0.51) ALDH1A1MAPTHTTNPC1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968568-B2 [1-(4-chloro-3-ethoxy-benzyl)-piperidin-4-yl]-(2-chloro-pyrimidin-4-yl)-amine; somatostatin receptor subtype 5 (SSTR5) antagonists; diabetes mellitus HOFFMANN-LA ROCHE INC. (US) 2011-06-28 US disclosed
EP-2044054-B1 PYRIMIDINE AND QUINAZOLINE DERIVATIVES AS MODULATORS OF SOMATOSTATINE RECEPTOR ACTIVITY HOFFMANN LA ROCHE (CH) 2011-06-08 EP disclosed
US-20100069413-A1 Pyrimidine and Quinazoline Derivatives CHRIST ANDREAS D 2010-03-18 US disclosed
US-7674804-B2 Pyrimidine and quinazoline derivatives as SST5 modulators HOFFMANN-LA ROCHE INC. (US) 2010-03-09 US disclosed
EP-2044054-A2 PYRIMIDINE AND QUINAZOLINE DERIVATIVES AS MODULATORS OF SOMATOSTATINE RECEPTOR ACTIVITY F. Hoffmann-Roche AG (CH) 2009-04-08 EP disclosed
US-20080045550-A1 Pyrimidine and quinazoline derivatives F. HOFFMANN-LA ROCHE AG (CH) 2008-02-21 US disclosed
WO-2008000692-A2 PYRIMIDINE AND QUINAZOLINE DERIVATIVES AS MODULATORS OF SOMATOSTATINE RECEPTOR ACTIVITY F. HOFFMANN-LA ROCHE AG (CH) 2008-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069413-A1 Pyrimidine and Quinazoline Derivatives SSTR5, SSTR3, NPY5R NOS2 1559/4885NOS1 1371/4885ALDH1A1 2667/4885
US-20080045550-A1 Pyrimidine and quinazoline derivatives SSTR5, SSTR3, NPY5R NOS2 1559/4885NOS1 1371/4885ALDH1A1 2667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.